Introduction
A frequent side effect of treatment of leukemia patients with chemotherapeutic drugs is the development of drug resistance. [1] [2] [3] [4] [5] [6] [7] [8] [9] Drug-resistant cells are often insensitive to multiple chemotherapeutic drugs that are structurally unrelated. In some cases, this phenomenon has been shown to be due to the increased expression of membrane transporters. [4] [5] [6] [7] [8] [9] These transporters belong to a large family of proteins that contain ATP-binding cassette (ABC) domains. Multidrug resistance protein-1 (Mdr-1 also known as P glycoprotein (Pgp)) was one of the first of these molecules to be identified to have a role in drug resistance. Inhibitors to some of these membrane transporters have been developed and evaluated in clinical trials. Unfortunately, these clinical trials have not yet yielded support for inclusion of these inhibitors in drug resistance therapy. [9] [10] [11] [12] An alternative therapeutic approach could be to target the growth and survival pathways that become activated in the drug-resistant cells. p53/MDM-2, Raf/MEK/ERK, PI3K/Akt and apoptotic pathways are frequently implicated in drug resistance of various types of cancers. [13] [14] [15] [16] [17] [18] [19] [20] The p53 transcription factor is a highly complex tumor suppressor gene, which is mutated in approximately 50% human cancers. 2, 18, [21] [22] [23] [24] It is often activated by genotoxic stresses, such as those generated upon doxorubicin treatment. p53 has numerous effects on cellular growth: it can induce cell cycle arrest through p21
Cip-1 and it can regulate the Raf/MEK/ ERK pathway by the discoidin domain receptor-1 protein. [25] [26] [27] [28] p53 can also control the transcription of many apoptotic molecules including Bcl-2 homology domain-3 (BH-3)-containing proteins: BAX, PUMA and NOXA. 2, 18, 29, 30 Dysregulation of the p53 pathway has been implicated in drug resistance in many different types of cancers; however, common problems in many of these studies are cause and effect. Many drug-resistant leukemia lines were derived after prolonged treatment of the patients with chemotherapeutic drugs. 9 Alternatively, many of the established human leukemia lines in culture are cytokineindependent and contain many mutations at key signaling and cell cycle regulatory genes. The drug-resistant derivative lines obtained from these established human leukemia lines might bear little resemblance to initial leukemia stem cells. In the following studies, we have investigated the effects of doxorubicin and p53 on the induction of drug resistance in hematopoietic cells. Decreased p53 activation was detected in the drug-resistant lines and introduction of DN p53 increased drug resistance indicating the importance of p53 gene function. Furthermore, suppression of p53 activity resulted in decreased effectiveness of MDM-2 and MEK inhibitors documenting the importance of p53 in the sensitivity to targeted therapy. Drugresistant cells displayed enhanced activation of the Raf/MEK/ ERK pathway and suppressed caspase activation upon doxorubicin treatment. The drug-resistant cells remained cytokinedependent, indicating that decreased p53 activation and drug resistance can be separated from cytokine-dependency.
Materials and methods

Cell lines and growth factors
Cells were maintained in a humidified 5% CO 2 incubator in RPMI-1640 medium (RPMI; Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Atlanta, GA, USA). The IL-3-dependent FL5.12 murine cell line 31 was cultured in this medium supplemented with 10% WEHI-3B(D À ) conditioned medium (WCM) as a source of IL-3. [32] [33] [34] [35] The drug-resistant FL/Doxo line was cultured in the same medium as FL5.12 cells with the addition of 10 nM doxorubicin (Sigma-Aldrich, St Louis, MO, USA). These cells have retained their IL3-dependency for over 3 years. The MEK inhibitor U0126 was purchased from Promega (Madison, WI, USA). The MDM-2 inhibitor Nutlin 3a was purchased from Calbiochem (EMD Chemicals, San Diego, CA, USA).
Limiting dilution analysis in doxorubicin
FL5.12 and drug-resistant FL/Doxo cells were plated at cell concentrations ranging from 0.1 to 100 000 cells per well in 96-well plates (Corning, Corning, NY, USA) 33, 34 in the presence of IL-3 doxorubicin (1, 10, 25, 50, 100 and 1000 nM). After isolation of clones, they were first expanded in 1 ml cultures in 24-well plates, and then subsequently in 5 ml cultures in 25 cm 2 tissue culture flasks as described. 33, 34 Infection of cells with retroviral vectors FL5.12 and FL/Doxo cells were infected with retroviral vectors encoding WT or DN p53, constitutively active (CA) (DStuI-MEK-LIDEMANE) or DN MEK1 (MEKLIDA) or an empty retroviral vector (pLXSN), as previously described. [36] [37] [38] Stably infected (WT and DN p53-and pLXSN-transduced) cells were selected with IL-3 þ 2 mg ml À1 G418 (Geneticin, Invitrogen). 34 Stably infected (DN and CA MEK1, BRAF(WT):ER* and BRAF(V600E): ER*) cells were selected with IL-3 þ 2 mg ml À1 puromycin (Sigma-Aldrich). The modified ER* domain responds to 4-hydroxy tamoxifen (4HT) 36 was purchased from SigmaAldrich and used at 500 nM to induce activation of the BRAF:ER* proteins. Full-length cDNAs encoding BRAF(WT) and BRAF (V600E) were subcloned adjacent to ER* into the modified pB3Puro retroviral vector.
Analysis of cell sensitivity to anticancer agents
Sensitivities of cells to doxorubicin, paclitaxel, daunorubicin, cisplatin or 5-flurouracil (all purchased from Sigma-Aldrich) were investigated by characterizing effects of these agents on proliferation. 18, 36, 39 Proliferation assays were performed to measure cellular growth under various conditions over a period of 5 days. Cells were resuspended in phenol-red-free RPMI containing 10% fetal bovine serum and IL-3. Cells were seeded in 96-well cell culture plates at a density of 2500 cells per well in 100 ml per well of cell culture medium. A 100 ml dose of treatment medium (chemotherapeutic drugs) was added to each well the day after cells were initially seeded. Cell culture plates were incubated in a cell culture incubator at 37 1C until the extent of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT; Sigma-Aldrich) reduction in each well was quantified. Inhibitory concentration 50% (IC 50 ) is defined in this context as the drug concentration that causes the cells to proliferate at a rate that is half as rapid as cells incubated in the absence of drugs. 18, 39, 40 Western blot analysis Cells were cultured and then protein lysates prepared as described. 36, 39, 40 Western blots were performed with antibodies specific for ERK; p53; caspases 3, 8 and 10; and PARP (poly(ADP-ribose)polymerase), as previously described. [39] [40] [41] Antibodies were purchased from Cell Signaling (Beverly, MA, USA).
Annexin-V/PI staining
One million cells were washed twice with phosphate-buffered saline and stained with 100 ml of labeling buffer (10 mM HEPES, 140 mM NaCl, 5 mM CaCl 2 , 0.5 mg PI (propidium iodide) and 1 ml Annexin-V-fluos (Roche Applied Science, Indianapolis, IN, USA), and incubated at 4 1C for 20 min as described. 36, 41 Labeling buffer was removed and the cells were resuspended in 400 ml of binding buffer (10 mM HEPES, 140 mM NaCl, 5 mM CaCl 2 ). Cells were immediately analyzed using a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA).
Real-time polymerase chain reaction
The real-time polymerase chain reaction (PCR) primer pairs used were: mouse b-actin (forward: 5 0 -GTATTCCCCTCCATCGTGG G-3 0 ; reverse: 5 0 -CTTTTCACGGTTGGCCTTAGG-3 0 ) and mouse p53 (forward: 5 0 -AGAGACCGCCGTACAGAAGAAGAA-3 0 ; reverse: 5 0 -TCCCGGAACATCTCGAAGCGTTTA-3 0 ). Total RNA was isolated by using the TRIZOL (Invitrogen) method and reverse-transcribed by iScript Select cDNA synthesis kit (Bio-Rad, Hercules, CA, USA) according with the manufacturer's instructions. Real-time PCR was performed with iQ SYBR Green Supermix (Bio-Rad) in a MyiQ thermocycler (Bio-Rad).
Standard curve was generated for primer sets using fivefold serial dilutions of untreated FL5.12 cells' DNA. PCR efficiencies were 92% for b-actin and 112% for p53, with correlation coefficients greater than 0.99. Quantization was done by comparing threshold cycle values for DNA from doxorubicintreated cell with the threshold cycle value for the control untreated cell's DNA, and by comparing threshold cycle values for FL5.12 cells DNA with the threshold cycle value for FL/ Doxo-resistant cells DNA. All quantizations were normalized to the control b-actin.
Results
Isolation and characterization of drug-resistant hematopoietic cells
To elucidate the mechanisms involved in the drug resistance of early hematopoietic cells, FL5.12 cells were plated in limitingdilution experiments in the presence and absence of IL-3 and different concentrations of doxorubicin in 96-well plates to isolate drug-resistant cells. Doxorubicin-resistant cells (FL/Doxo) were recovered in the presence of IL-3 and either 10 or 100 nM doxorubicin, but not 1000 nM, doxorubicin (Figure 1a) . No clones were obtained in the absence of IL-3 documenting the strict IL-3 dependency of this cell line, even when it was grown in the presence of doxorubicin. Approximately 1 in 10 (frequency 1 Â 10 À1 ) FL5.12 cells form a colony in the presence of IL-3 þ 10 nM doxorubicin, whereas only 1 in 500 (frequency 2 Â 10 À3 ) FL5.12 cells form a colony in the presence of IL-3 þ 100 nM doxorubicin. Approximately 25 different clones were isolated, expanded into 0.2, 1, 5, 10 and then 25 ml cultures. These individual clones were frozen down. Three different clones were chosen for further study: FL/Doxo-1, FL/Doxo-2 and FL/Doxo-3. These clones have been maintained continuously in 10-100 nM doxorubicin and IL-3 for the past 3 years. The results presented in this paper were obtained with FL/Doxo-1, hereafter referred to as FL/Doxo. Similar results were obtained with FL/Doxo-2 and FL/Doxo-3.
The doxorubicin-selected cells that were maintained in 10 nM doxorubicin and IL-3 had a higher cloning efficiency in doxorubicin than the parental FL5.12 cells, as 1 in 1.5 cells formed a colony in medium containing 10 nM doxorubicin and 
À2
) formed a colony when the cells were plated in 100 nM doxorubicin and IL-3 ( Figure 1b) . These represent approximately 7-and 8.3-fold increases in cloning efficiency in 10 and 100 nM doxorubicin, respectively, as compared with the unselected FL5.12 cells. When IL-3 was eliminated from the culture conditions, no colonies were obtained, indicating that the cells retained their cytokine-dependence (data not presented). Conversion of FL5.12 cells to cytokine-independence is almost always associated with leukemic transformation. [32] [33] [34] Thus, with the cytokine-dependent drug-resistant FL/Doxo cells, it is possible to examine some of the biochemical processes involved in the emergence of drug-resistant clones independent of the changes involved in malignant transformation.
The growth of the drug-sensitive and -resistant cells in the presence and absence of doxorubicin was determined (Figure 2 ). FL5.12 and FL/Doxo cells displayed equal growth rates when they were plated in medium containing IL-3 ( Figure 2a ). In contrast, the FL/Doxo cells grew better in the presence of IL-3 and doxorubicin (Figure 2b ) than the parental FL5.12 cells. Again, neither cell line grew in the absence of IL-3.
The sensitivities of the parental and doxorubicin-resistant cells to five common chemotherapeutic drugs were examined ( Figure 3 ; Table 1 ). The doxorubicin-resistant cells had increased IC 50 for doxorubicin, paclitaxel and daunorubicin, but not 5-flurouracil or cisplatin (Table 1) . A representative IC 50 analysis is presented in Figure 3 .
The effects of doxorubicin, daunorubicin and paclitaxel on the induction of apoptosis were determined ( Figure 4 ; Table 2 ). The FL/Doxo cells were more resistant to the induction of apoptosis by doxorubicin (Figure 4a (Table 2) , than the parental FL5.12 cells.
Decreased caspase activation in doxorubicin-resistant cells
To determine whether the results observed upon induction of apoptosis as detected by Annexin-V/PI assay also correlated with altered induction of caspase cascades; the activation of caspases 3, 8 and 10 and PARP cleavage were monitored by western blot analysis in FL5.12 and FL/Doxo cells after they were treated with increasing concentrations of doxorubicin for 24 h ( Figure 5 ). Treatment of FL5.12 cells for 24 h with 100 and 1000 nM doxorubicin induced caspase 3 cleavage. In contrast, cleavage of caspase 3 in FL/Doxo cells was only detected after they were treated with 1000 nM doxorubicin for 24 h. These results were quantified by densitometric scanning and are included underneath the western blot figure. Furthermore, there was more cleavage of the caspase 3 substrate PARP in the doxorubicin-sensitive than doxorubicin-resistant cells upon doxorubicin treatment.
To determine whether treatment with doxorubicin also induced the extrinsic apoptotic pathway, the activation of caspases 8 and 10 was compared in the doxorubicin-sensitive and -resistant cells ( Figure 5 ). Treatment of the doxorubicinsensitive cells with doxorubicin resulted in a greater increase in caspases 8 and 10 activation than what was detected in the drug-resistant cells. This was determined by the decrease in total caspase 8 and 10 proteins levels, which were normalized to the total levels of b-tubulin.
Lack of elevated drug efflux activity in doxorubicin-resistant cells
To determine whether drug efflux activity was elevated in FL/Doxo in comparison with FL5.12 cells, a rhodamine-123 dye exclusion assay was performed by flow cytometric analysis. The drug-resistant and -sensitive cells exhibited similar levels of drug efflux activity. Furthermore, these cells displayed similar abilities to efflux daunorubicin. These drug efflux assays were performed four times (data not presented).
Decreased induction of p53 in drug-resistant cells
The ability of doxorubicin to induce p53 was examined in drugsensitive and -resistant cells to test the hypothesis that there was a difference in the p53 response in the two different types of cells ( Figure 6 ). FL5.12 and FL/Doxo cells were deprived of IL-3 12 and FL/Doxo cells were determined as described. 18, 39, 40 The IC 50 s for doxorubicin and daunorubicin were estimated from where the half-maximal growth was observed and is indicated with an arrow on the X-axis. The IC 50 with paclitaxel is based on half of maximum inhibition observed, which was at 0.75 relative growth (maximum growth ¼ 1, minimum growth ¼ 0.5). Arrows indicate where the IC 50 can be estimated. These experiments were repeated four times with three different clones and similar results were observed. p53, signaling pathways and hematopoietic drug resistance JA McCubrey et al induction of ERK1/2 was also examined in these cells. Doxorubicin did not induce high levels of activated ERK1/2 in drug-sensitive FL5.12 cells. In contrast, higher levels of activated ERK1/2 were detected in FL/Doxo cells. As a loading control, the presence of total ERK was examined in these samples. Relatively equal levels of total ERK1/2 were detected in both cell lines. Thus, drug-resistant cells had decreased the induction of p53 after doxorubicin treatment and elevated activated ERK1/2.
Increased proteasomal degradation of p53 in doxorubicin-resistant cells
Elucidating the mechanisms responsible for the increased expression of p53 in the doxorubicin-sensitive cells in comparison with doxorubicin-sensitive cells are important in understanding how hematopoietic cells become drug resistant. Drug-resistant cells may have higher levels of proteasomal degradation than normal hematopoietic cells. To address this suggestion, we exposed doxorubicin-sensitive FL5.12 and doxorubicin-resistant FL/Doxo cells to the proteasomal inhibitor MG132 and doxorubicin. As presented in Figure 6 , the doxorubicin-sensitive cells expressed more p53 than the doxorubicin-resistant cells. Exposure to the proteasomal inhibitor (10 mM MG132) resulted in stabilization of p53 in both cell lines, as higher levels of the p53 protein were detected. However, the stabilization of p53 in the doxorubicin-resistant cells was more dramatic, as no p53 was detected in the absence of the proteasomal inhibitor, whereas it was detected upon treatment with the proteasomal inhibitor ( Figure 7) . These results indicate that there is a higher level of proteasomal degradation in the drug-resistant cells.
As a control, the effects of the proteasomal inhibitor on the levels of activated and total ERK were examined. As presented in the original Figure 6 , the doxorubicin-resistant cells expressed higher levels of active ERK than the doxorubicin-sensitive cells. In contrast, exposure to the proteasomal inhibitor did not result in an increase in the levels of activated ERK 1/2 detected. Furthermore, the proteasomal inhibitor did not alter the levels of total ERK detected in either cell line.
To determine if there was a difference in p53 gene expression, we examined the levels of p53 mRNA by real-time PCR. The levels of p53 mRNA transcripts were higher in the drug-resistant cells than in the drug-sensitive cells, especially at higher doxorubicin concentrations (Figure 7 ). At these higher doxorubicin concentrations, the cell viabilities of the drug-sensitive FL5.12 cells decreased compared with the doxorubicin-resistant cells, which may have led to this decrease in the relative expression of p53 in the drug-sensitive FL5.12 cells. Thus, the lack of p53 expression in the drug-resistant cells is not due to a lack of mRNA expression, rather it is due to increased proteasomal degradation in these cells.
Consequences of DN p53 expression on drug sensitivity
To further examine the roles of p53 on chemosensitivity, DN p53 and WT p53 constructs 38 were introduced into the cells and the doxorubicin IC 50 s were determined by MTT analysis ( 36 The fold-induction of apoptosis at each drug concentration was determined upon comparison with untreated cells. These experiments were performed three times and the means and s.d. are presented. 
Effects of a MDM2 inhibitor on drug sensitivity
To further determine the role of p53 on drug sensitivity, the effects of the MDM2 inhibitor Nutlin 3a were determined (Table 4) . Nutlin 3a inhibits the ability MDM-2 to ubiquitinate p53, which results in increased stability of p53, thereby prolonging the effects of p53. 2,42-45 p53 may be a key target in leukemia as it regulates both Raf/MEK/ERK and PI3K/Akt pathways. p53 is, in turn, also regulated by these pathways.
2,3
The sensitivities of FL5.12, FL5.12 þ DN p53, FL/Doxo and FL/ Doxo þ DN p53 cells to Nutlin 3a were determined. These cell lines were not significantly affected when they were treated with concentrations of Nutlin 3a up to 5000 nM ( (Table 4) . Again, interactions between doxorubicin and Nutlin 3a were observed in FL5.12 and FL/Doxo cells, which decreased the IC 50 for doxorubicin. However, similar effects on the doxorubicin IC 50 were not observed in the cells transduced with DN p53 (FL5/12 þ DN p53 or FL/Doxo þ DN p53). Hence functional p53 activity was required for interaction between Nutlin 3a and doxorubicin, which increased cell death.
Role of the Raf/MEK/ERK pathway in hematopoietic drug resistance
As shown earlier in Figure 6 , FL/Doxo cells expressed elevated levels of activated ERK in comparison with drug-sensitive cells. To further examine the roles of Raf/MEK/ERK on the chemosensitivity of the cells, a DN MEK construct 37 was introduced into the cells and doxorubicin IC 50 s determined by MTT analysis (Table 5) . Cells were infected with retroviruses encoding DN MEK (MEK LIDA) or, as a control, an empty retroviral vector (pLXSN). DN MEK1 has serines 218 and 222 mutated to alanines, which cannot be phosphorylated and activated by Raf. DN MEK1 is inactive and interferes with endogenous MEK1. 37 Introduction of DN MEK1 reduced the IC 50 for doxorubicin in FL5.12 cells by 5.5-fold and in FL/Doxo cells 5.3-fold (Table 5) . Moreover, introduction of the DN MEK1 into the FL/Doxo and FL5.12 cells reduced the cloning efficiency in doxorubicin approximately threefold (data not presented). However, even after introduction of the DN MEK1 gene, the doxorubicinresistant cells were approximately 7.3-fold more resistant to doxorubicin than the parental cells (Table 5) .
The effects of elevated MEK/ERK expression on the drug resistance of FL5.12 cells were also examined by the introduction of a CA MEK1 gene (DStuI-MEK-LIDEMANE), 37 hereafter referred to as MEK1 (CA). MEK1 (CA) has serines 218 and 222 mutated to glutamic acids, and a 60 bp fragment (DStuI) coding for an alpha helix from MEK 1 deleted, making MEK1 CA FL5.12 cells transduced with MEK1 (CA) (FL þ MEK1 (CA)) show a 3.2-fold increase in the doxorubicin IC 50 increase upon addition of 4HT to the medium (Table 6 ). The resistance of FL/BRAF(V600E):ER* cells in the absence of 4HT stimulation was approximately twofold higher than FL5.12 cells, likely due to some activity of the BRAF(V600E):ER* protein in the absence of 4HT.
Finally, the effects of inhibition of MEK1 on the sensitivity of doxorubicin were examined by treatment of the cells with an MEK1 inhibitor (Table 7) . When FL5.12 cells are cultured in the presence of IL-3, they are extremely resistant to the effects of MEK1 inhibitors. In these experiments, the results with the UO126 MEK inhibitor are presented. Similar results were observed with other MEK inhibitors (for example, PD98059 and others, data not shown).
The doxorubicin-resistant lines (FL/Doxo and FL/Doxo þ MEK1 (CA)) were slightly more sensitive to the MEK1 inhibitor; however, the IC 50 was not obtained until 42000 nM UO126 was added. The effects of co-addition of the MEK inhibitor and doxorubicin were examined to determine if addition of a suboptimal concentration of doxorubicin would increase the sensitivity to the MEK1 inhibitor. Addition of 10 nM doxorubicin did not significantly (1.2-fold) increase the sensitivity of FL5.12 cells to the MEK inhibitor. In contrast, addition of 10 nM doxorubicin increased the sensitivity of FL/Doxo and FL/Doxo þ MEK1 (CA) cells by 10.3-and 35-fold, respectively. Such a sensitization was not observed in FL/Doxo þ DN p53 cells.
The reciprocal experiments were performed by examining the effects of a suboptimal concentration of the MEK inhibitor on the doxorubicin IC 50 . When FL5.12 cells were treated with doxorubicin and a suboptimal concentration of an MEK inhibitor, they did not show any decrease in the doxorubicin IC 50 (Table 7) . In contrast, when the drug-resistant FL/Doxo cells were cultured with the suboptimal dose of the MEK inhibitor, the doxorubicin IC 50 decreased approximately 3.7-fold. The drug-resistant FL/Doxo þ MEK1 (CA) cells were more sensitive to the MEK inhibitor as their IC 50 decreased 7.3-fold. In contrast, drug-resistant FL/Doxo þ DN p53 cells were not sensitive to suboptimal concentrations of the MEK1 inhibitor, indicating that a functional p53 activity was necessary for sensitivity to the MEK1 inhibitor. Determined by MTT analysis as described in the legend for Table 1 . Determined by MTT analysis as described in the legend for Table 1 . 
Determined by MTT analysis as described in the legend for Table 1 . These experiments were performed the same number of times as the experiments presented in Table 3 . Determined by MTT analysis as described in the legend for Table 1 . IL-3 or IL-3+500 nM 4HT was added at the start of the experiments; the different dilutions of doxorubicin were added 1 day later, and then the cells were incubated for 4 days and processed as the other MTT experiments.
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Discussion
We have investigated some of the mechanisms by which hematopoietic cells become resistant to chemotherapeutic drugs commonly used to treat leukemia patients. One advantage of our model system is that we can determine some of the early biochemical events involved in conversion to drug resistance, as our drug-resistant cells remained cytokine-dependent. Initially, we had thought that our drug-resistant cells might have become drug resistant by increased drug efflux. However, the drug-resistant cells did not exhibit increased efflux of either rhodamine-123 or daunorubicin, as determined by flow cytometric analysis. Furthermore, the cells did not display increased expression of either Mdr-1 or MRP-1, as determined by real-time PCR or western blot analysis. In fact, these cells do not appear to express Mdr-1 (data not presented). Thus, we focused our investigation on the role of p53 and the Raf/MEK/ERK pathways, which have been associated with drug resistance.
We observed decreased induction of p53 and increased induction of the Raf/MEK/ERK pathway in the drug-resistant FL/ Doxo cells compared with the drug-sensitive FL5.12 cells upon doxorubicin treatment. The effects of p53 expression on the drug resistance of the cells were further examined by introduction of WT and DN p53 constructs into the cells. Introduction of DN p53, but not WT p53, increased drug resistance. These results indicate that the p53 protein present in the FL/Doxo cells is functional, as the drug resistance of these cells can be altered by introduction of a DN p53 but not decreased by introduction of a WT p53 protein. Inhibiting the effects of MDM-2 with Nutlin 3a increased the sensitivity of cells with WT p53 to doxorubicin, but not the sensitivity of cells with mutant p53. Thus, p53 is potentially an important target in the treatment of drug-resistant leukemia. [44] [45] [46] Leukemic stem cells are frequently drug resistant. [47] [48] [49] Our results point out that one of the first events involved in this process is decreased expression of the p53 tumor suppressor protein. Low levels of p53 are observed in acute myeloid leukemia (AML) blasts, whereas p53 mutations may not be so common. However, p53 mutations are observed after chemotherapy of various hematopoietic malignancies. [50] [51] [52] [53] [54] [55] [56] The interactions between the p53 and Ras/Raf/MEK/ERK pathways are complex and a focal point in the sensitivity of cells to chemotherapeutic drugs such as doxorubicin. Doxorubicin, through reactive oxygen species and other molecular mechanisms, may induce p53, which in turn promotes the expression of pro-apoptotic genes, such as Noxa and Puma. p53 Also induces p21
CipÀ1 and cell cycle arrest. 57, 58 Hence, a primary effect of doxorubicin is the induction of apoptosis and cell cycle arrest, especially in cells such as FL5.12 cells, which have WT p53. We observed that the drug-resistant FL/Doxo cells expressed higher amounts of activated ERK than the drugsensitive FL5.12 cells. Activation of the Ras/Raf/MEK/ERK pathway in the drug-resistant cells may result in elevated Mdm-2 expression, as there are Ets and Ap-1 sites in the promoter region of Mdm-2. 59 Ets-1 and Ap-1 can be posttranscriptionally modified by ERK. Hence, elevated ERK in the drug-resistant cells may result in increased Mdm-2 expression, which in turn increases the ubiquitination and degradation of p53. Consistent with this hypothesis, we observed that the stability of the p53 protein in the drug-resistant cells was decreased in comparison with the p53 protein in the drugsensitive cells. Treatment of the drug-resistant cells with proteasome inhibitors resulted in increased detection of the p53 protein in the drug-resistant cells. In contrast, the p53 gene was determined to be transcribed in both drug-sensitive andresistant cells. Hence, the level of proteasomal degradation of p53 was higher in the drug-resistant cells, suggesting a possible mechanism for their drug resistance. Recently it has also been shown that the Raf/MEK/ERK pathway regulates the subcellular localization of p53 and the significance of transcriptiondependent and -independent pathways in p53-mediated apoptosis. 45 These studies also demonstrated that MEK inhibitors were able to synergize with Nutlin 3a in the induction of apoptosis in AML cells. Clearly, there are important interactions between Raf/MEK/ERK and p53 in the regulation of apoptosis in hematopoietic cells and we may be able to target these pathways in drug-resistant cells.
There may be other sites of interaction between the p53 and Ras/Raf/MEK/ERK signaling cascades, which are important for sensitivity to chemotherapeutic drugs. Doxorubicin may stimulate p53 expression, which in turn induces the discoidin domain receptor-1 gene, which can activate Ras as well as the Raf/MEK/ ERK pathway. 60, 61 This may serve as another site of cross-talk between these two pathways. The role of discoidin domain receptor-1 in the induction of the Raf/MEK/ERK pathway and chemoresistance of hematopoietic precursor cells is being investigated. This cross-talk may be a general phenomenon, as we have observed that upon restoration of p53 activity to normally p53-deficient prostate cancers, induction of discoidin domain receptor-1 and the Raf/MEK/ERK pathway occur.
Increasing the level of either BRAF or MEK activity by introduction of BRAF or MEK1 genes increased the drug resistance of the cells. In contrast, introduction of DN MEK1 genes decreased the drug resistance of the cells. Additional studies with MEK inhibitors have indicated that the drugresistant cells are hypersensitive to targeting MEK, whereas the drug-sensitive cells are not as sensitive. Furthermore, introduction of an activated MEK1 gene conferred increased sensitivity on the MEK1 inhibitor than cells that lacked the activated MEK1 gene. Although the Raf and MEK genes have not been observed to be frequently mutated in leukemia, mutations in upstream receptors (for example, Flt-3) and Ras activate the Raf/MEK/ERK pathway in various hematopoietic neoplasias. 2, 3 These mutations may render these hematopoietic cells exquisitely sensitive to inhibitors that target this pathway. 3, 15 Germline mutations in C-Raf (Raf-1), which may contribute to malignant transformation, have been identified in patients with therapy-related AML, p53, signaling pathways and hematopoietic drug resistance JA McCubrey et al which may predispose these individuals to cancer. 62 These results point toward important roles of the Raf/MEK/ERK pathway in the drug resistance of hematopoietic cells.
An end result of the dysregulation of p53 and the Raf/MEK/ ERK signal transduction pathways is a decrease in the induction of apoptosis. Lower levels of activation of caspases 3, 8 and 10 were observed in the doxorubicin-resistant cells when they were cultured in IL-3 þ doxorubicin than in the parental cells. This resulted in less apoptosis in the drug-resistant cells than in the drug-sensitive cells.
Drug resistance remains a significant problem in cancer therapy. It is especially a problem in hematopoietic cancers, as they often become drug resistant after chemotherapy. Drug resistance is also frequently observed in therapy-associated AML and myelodysplastic syndrome, which arise after treatment of malignancies with drugs such as topoisomerase inhibitors or alkylating agents. The drug resistance in therapy-associated AML and myelodysplastic syndrome is closely related to a high frequency of p53 mutations, which is about 20-30%, whereas in de novo AML it is less than 10%. 51, 52 These and other observations highlight the clinical significance of mutated p53 in drug resistance of hematopoietic neoplasia. [51] [52] [53] [54] Our model system allows us to understand some of the early changes that occur to result in drug-resistant hematopoietic cells, as our drug-resistant cells remained cytokine-dependent. Cytokinedependent murine hematopoietic cells do not form tumors in immunocompromised or synergetic mice. [33] [34] [35] [36] Some of the mutations preexisting in human leukemias may contribute to drug resistance and alter the expression of signal transduction, apoptosis and molecules involved in drug transport. Our model system may allow us to identify the key pathways necessary for drug resistance of hematopoietic cells and allow their effective targeting.
